Signature Initial Date

Pragya B. Gupta, M.D., F.R.C.S. (Edin), D.A.B.P.M., C.P.I.

Medical Director
Advanced Pain Treatment Center
Tel: (859)3314159; Fax: (859)3314163
Otrimed Clinical Research
Tel: (859) 7571359; Fax: (859) 3316600
Mailing Address:
162 Barnwood Drive
Edgewood, KY 41017
pbgupta@aptcmd.com
Cell: (859) 4682583.

EDUCATION & Qualification:

2016: Certified Physician Investigator by Academy of Clinical Research Professionals (Exam09/16).
2001: Diplomate of American Board of Pain Medicine – recertification 2011, # 08901
2000: ABA subspecialty certification in Pain Medicine – recertification 2011, # 32482
1999: American Board of Anesthesiology (ABA) certification (Indefinite Expiry) #32482
1994: Fellow of the Royal College of Surgeons of Edinburgh (General Surgery), United Kingdom.
1985: Bachelor of Medicine and Bachelor of Surgery (M.B.B.S.), R. G. Kar Medical College, University of Calcutta, Calcutta, West Bengal, India

Education (Clinical Research)

07/2015: Appraisal of Evidence in Studies of Diagnostic Tests and Strategies, Evidence Based Medicine – Part II, Spine Interventional Society, Educational Program (SIS).
03/2016: Good Clinical Practice – CITI Program – GCP E6 ICH course.

MEDICAL TRAINING:

1998-1999: Fellowship in Pain Management, **Tufts Medical Center**, Boston, MA
1995-1998: Residency Training in Anesthesiology, **Tufts Medical Center**, Boston, MA
1994-1995: Internship in General Surgery, **University of Illinois**-MGH Program, Chicago, IL.

Academic Appointment:

07/2003- University of Kentucky Medical Center, Assistant Professor- AHEC Faculty-volunteer, Department of Anesthesiology/ Pain Medicine, Lexington, KY 40536-0284, Tel: (859) 323 1918

Clinical Research Experience (PI):

- A safety and Efficacy Evaluation of BLI801 Laxative in Adults Experiencing Non-Idiopathic Constipation.
- A phase 3 prospective multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single injection of Rexlemastrocel-L alone or combine with hyaluronic acid in subjects with chronic discogenic lumbar back pain through 12 months.
- A phase 2A, open label, Sequential, Dose Escalation Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of MDT-15 in subjects with Lumbosacral Radiculopathy.

- A Phase 3 Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled , Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) in Opioid-experienced Subjects With Uncontrolled Moderate to Severe Chronic Low back Pain and a History of Opioid-induced Constipation who require Around-the-clock Opioid therapy.
- A phase 3 randomized, double-blind, placebo-controlled, parallel-group Study of Naldemedine in the treatment of Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy.

- A non-randomized, active, prospective post-market trial to determine the continuing evaluation and periodic reporting of safety and effectiveness of an implantable stimulator on the effects of chronic low back pain. Phase 4.

- A phase 3, randomized double blind placebo controlled parallel group study of the efficacy and safety of pregabalin (bid) in subjects with post–traumatic peripheral neuropathic pain.

- Protocol 15Q- MC-CGAG, A phase 3, Randomized, Double-Blind, and Placebo controlled study of LY2951742 in Patients with Episodic Migraine

- A phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 IN Migraine Prevention.

- A Phase 3 randomized double blind parallel group multicenter placebo controlled dose ranging study to evaluate glycemic effect, safety & tolerability of Metformin delayed release in subjects with Type 2 Diabetes Mellitus.

- A phase 3 Randomized, double blind, placebo and active controlled multicenter, parallel group study of the analgesic efficacy and safety of Tanezumab in adult subjects with chronic low back pain.

- A phase 3, Randomized, 16 week, Multi – Phase, double blind, placebo controlled study to evaluate the efficacy, safety and tolerability of Fulranumab as a mono therapy in subjects with signs and symptoms of Osteoarthritis of the hip or knee.

- A phase 3, Randomized double blind, active controlled, multicenter study of long term safety and efficacy of subcutaneous administration of Tanezumab in subjects with Osteoarthritis of the Hip or Knee. A4091058.

-

Research Experience - SI:

- Induction, Stabilization, Adherence and Retention Trial (ISTART)-A randomized non-inferiority multicenter study to assess early treatment efficacy of OX 219 versus Suboxone and to explore switching between treatments. Phase 3 study.
- The SPD 489-322 Phase 3, Multicenter, Randomized, Double- blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective treatment with an Antidepressant. Phase 3study.
- The SPD489-322 A Phase 3, Open-label, Multicenter, 12- month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant. Phase 3.

- Randomized, Double – Blind, Place o Controlled Study of LY2951742 in Patients with Episodic Migraine. –Phase 2b

- Efficacy and Safety Study of ALKS 5461 for the adjunct treatment of Major Depressive Disorder (the FORWARD – 3 Study.
- A phase 3 Efficacy and Safety study of ALKS 5461 for the adjunctive treatment of Major Depressive Disorder, the Forward 3 study.
- A Phase IIA double blind, placebo controlled multicenter study of Sirukumab as adjunctive treatment to a monoaminergic antidepressant in adult with Major Depressive Disorder.

Work Experience:

02/2002–Present	Medical Director- Advanced Pain Treatment Center, Edgewood, KY 41017
01/2001-02/2002	Medical Director, Ohio Valley Chronic Pain Center, Warsaw, KY 41095
07/1999- 12/2000	Director, Pain Control Center, Clark Regional Medical Center, Winchester, KY 40391

Hospital Affiliation:

01/2000-Present	St. Elizabeth Medical Center, 1 Medical Village Drive, Edgewood, KY 41017:
04/2006-Present	Mercy Fairfield Hospital, 3000 Mac, Road, Fairfield, OH 45014
05/2009-Present	West Chester Medical Center, 7700 University Drive, West Chester, OH 45069

Licensure:

6/1999-Present	Kentucky Board of Medical Licensure (Active)
12/1997-Present	Commonwealth of Massachusetts (Active)
02/2003-Present	Medical Board of Ohio (Active)
8/2006-Present	DEA: BG xxxxx45 (KY), XG xxxxx45, FG xxxxx54 (OH) Expires: 9/30/2018.
09/17/1993	ECFMG: 0-xxx-xxx-5.

Publications:

- Spontaneous Rupture of Spleen Secondary to Metastatic Carcinoma. PB Gupta & LHarvey, British Journal of Surgery. Vol. 80, May 1993, 613.
- Book Review: Sickle Cell Pain by Samir Ballas, IASP Press Seattle. PB Gupta, DB Carr; Acute Pain (International Journal of Acute Pain Management). Volume 1 (5) Dec. 1998.

Research Interests:

Low back pain & Neck pain
Major Joint pain (degenerative and post traumatic OA)
Regenerative Medicine use in chronic painful degenerative conditions
Minimally invasive spinal decompression and discectomy procedures
Neuroaugmentaion for managing chronic neuropathic pain, post traumatic neuropathy and Complex
Intrathecal targeted drug delivery for managing neuropathic and nociceptive pain.

Professional Membership:

- North American Spine Society (NASS)
- Spine Intervention Society (SIS)
- American Academy of Pain Medicine (AAPM)
- North American Neuromodulation Society (NANS)
- World Institute of Pain (WIP)
- Massachusetts Medical Society (MMS)
